Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03377049 · ClinicalTrials.gov registry record · Phase 4
Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT03377049 is a Phase 4 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 11 participants.
The verdict
NCT03377049, a Phase 4 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
The investigators propose a technique using cone beam CT perfusion (CBCTP) imaging with an acetazolamide challenge as a potential diagnostic tool to detect a defect in cerebral autoregulation at a time when it has not yet caused clinically apparent signs or symptoms. 30 participants will be enrolled at the University of Wisconsin - Madison and can expect to be on study for about 2 weeks.
Interventions
- DRUG Acetazolamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2019-07-28 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03377049
The ClinicalTrials.gov registry entry for NCT03377049 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Acetazolamide is the first listed.
NCT03377049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03377049 about?
NCT03377049 is a clinical study titled "Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm". The investigators propose a technique using cone beam CT perfusion (CBCTP) imaging with an acetazolamide challenge as a potential diagnostic tool to detect a defect in cerebral autoregulation at a time when it has not yet caused clinically apparent signs or symptoms. 30 participants will be enrolled...
What is the current status of trial NCT03377049?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2019-07-28. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT03377049?
The interventions under investigation include: Acetazolamide (DRUG).
Who is sponsoring clinical trial NCT03377049?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.